Company news
Compass Therapeutics, Inc. news in 2024
Compass Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
December 9, 2024
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
December 1, 2024
Compass Therapeutics to Participate in Upcoming Investor Events
November 12, 2024
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
November 11, 2024
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 7, 2024
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
October 3, 2024
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
August 11, 2024
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
August 6, 2024
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
August 5, 2024
Compass Therapeutics Announces CEO Transition
May 27, 2024
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual...
May 22, 2024
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
May 12, 2024
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
April 24, 2024
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
April 15, 2024
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
April 11, 2024
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
April 9, 2024
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 8, 2024
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 20, 2024
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
February 28, 2024
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
February 27, 2024